dc.creator | Manolakis A.C., Christodoulidis G., Kapsoritakis A.N., Georgoulias P., Tiaka E.K., Oikonomou K., Valotassiou V.J., Potamianos S.P. | en |
dc.date.accessioned | 2023-01-31T08:56:50Z | |
dc.date.available | 2023-01-31T08:56:50Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.3748/wjg.v23.i3.437 | |
dc.identifier.issn | 10079327 | |
dc.identifier.uri | http://hdl.handle.net/11615/76277 | |
dc.description.abstract | AIM: To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein (AHSG/fetuin A) and potential associations with disease and patient characteristics. METHODS: AHSG serum levels were determined in treatment-naïve newly-diagnosed patients, 96 with ulcerative colitis (UC), 84 with Crohn's disease (CD), 62 with diarrhea-predominant or mixed irritable bowel syndrome (IBS, D- and M- types) and 180 healthy controls (HC), by an enzyme linked immunosorbent assay (ELISA). All patients were followed for a minimum period of 3 years at the Gastroenterology Department of the University Hospital of Larissa, Greece. C-reactive protein (CRP), anti-glycan antibodies, anti-Saccharomyces cerevisiae mannan antibodies IgG, anti-mannobioside carbohydrate antibodies IgG, anti-laminariobioside carbohydrate antibodies IgG and anti-chitobioside carbohydrate antibodies IgA were also determined via immunonephelometry and ELISA, respectively. RESULTS: The mean ± SE of serum AHSG, following adjustment for confounders, was 0.32 ± 0.02 g/L in IBD, 0.32 ± 0.03 g/L in CD and 0.34 ± 0.03 g/L in UC patients, significantly lower than in IBS patients (0.7 ± 0.018 g/L) and HC (0.71 ± 0.02 g/L) (P < 0.0001, in all cases). AHSG levels were comparable between the CD and UC groups. Based on AHSG levels IBD patients could be distinguished from HC with about 90% sensitivity and specificity. Further adjusted analysis verified the inverse association between AHSG and penetrating, as well as stricturing CD (partial correlation coefficient: -0.45 and -0.33, respectively) (P < 0.05). After adjusting for confounding factors, inverse correlations between AHSG and CRP and the need for anti-TNFα therapy or surgery, were found (partial correlation coefficients: -0.31, -0.33, -0.41, respectively, P < 0.05, in all cases). Finally, IBD individuals who were seropositive, for at least one marker, had AHSG levels falling within the two lower quartiles (OR = 2.86, 95%CI: 1.5-5.44, P < 0.001) while those with at least two serological markers positive exhibited AHSG concentrations within the lowest quartile (OR = 5.03, 95%CI: 2.07-12.21, P < 0.001), after adjusting for age, sex and smoking. CONCLUSION: AHSG can be used to distinguish between IBD and IBS patients or HC while at the same time "predicting" complicated disease behavior, need for therapy escalation and surgery. Moreover, AHSG may offer new insights into the pathogenesis of IBD, since it is involved in key processes. © 2017 Baishideng Publishing Group Inc. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | World Journal of Gastroenterology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010004827&doi=10.3748%2fwjg.v23.i3.437&partnerID=40&md5=7d2d9db2e3ca75c0bf206af992931a67 | |
dc.subject | autoantibody | en |
dc.subject | C reactive protein | en |
dc.subject | chitobioside carbohydrate antibody | en |
dc.subject | corticosteroid | en |
dc.subject | fetuin A | en |
dc.subject | immunoglobulin A antibody | en |
dc.subject | immunoglobulin G antibody | en |
dc.subject | immunosuppressive agent | en |
dc.subject | laminariobioside carbohydrate antibody | en |
dc.subject | mannobioside carbohydrate antibody | en |
dc.subject | mesalazine | en |
dc.subject | Saccharomyces cerevisiae mannan antibody | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | unclassified drug | en |
dc.subject | AHSG protein, human | en |
dc.subject | biological marker | en |
dc.subject | C reactive protein | en |
dc.subject | fetuin A | en |
dc.subject | immunoglobulin A | en |
dc.subject | immunoglobulin G | en |
dc.subject | adult | en |
dc.subject | Article | en |
dc.subject | controlled study | en |
dc.subject | Crohn disease | en |
dc.subject | diarrhea | en |
dc.subject | down regulation | en |
dc.subject | female | en |
dc.subject | Greek (people) | en |
dc.subject | human | en |
dc.subject | inflammatory bowel disease | en |
dc.subject | irritable colon | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | receiver operating characteristic | en |
dc.subject | remission | en |
dc.subject | sensitivity and specificity | en |
dc.subject | smoking | en |
dc.subject | ulcerative colitis | en |
dc.subject | aged | en |
dc.subject | blood | en |
dc.subject | comparative study | en |
dc.subject | Crohn disease | en |
dc.subject | enzyme linked immunosorbent assay | en |
dc.subject | follow up | en |
dc.subject | Greece | en |
dc.subject | middle aged | en |
dc.subject | photometry | en |
dc.subject | serology | en |
dc.subject | ulcerative colitis | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | alpha-2-HS-Glycoprotein | en |
dc.subject | Biomarkers | en |
dc.subject | C-Reactive Protein | en |
dc.subject | Colitis, Ulcerative | en |
dc.subject | Crohn Disease | en |
dc.subject | Down-Regulation | en |
dc.subject | Enzyme-Linked Immunosorbent Assay | en |
dc.subject | Female | en |
dc.subject | Follow-Up Studies | en |
dc.subject | Greece | en |
dc.subject | Humans | en |
dc.subject | Immunoglobulin A | en |
dc.subject | Immunoglobulin G | en |
dc.subject | Irritable Bowel Syndrome | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Nephelometry and Turbidimetry | en |
dc.subject | Sensitivity and Specificity | en |
dc.subject | Serologic Tests | en |
dc.subject | Baishideng Publishing Group Co | en |
dc.title | (2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease | en |
dc.type | journalArticle | en |